Palisade Bio (PALI) EPS (Weighted Average and Diluted) (2016 - 2026)
Palisade Bio (PALI) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, up 89.36% year-over-year from -$0.03 in Q1 2025, and down 104.63% quarter-over-quarter from $1.08 in Q4 2025.
Palisade Bio (PALI) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
Palisade Bio (PALI) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.05, up 89.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.07 (up 101.03% YoY), and the FY2025 annual result was -$0.3, up 97.06% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$0.05 in Q1 2026 per PALI's latest filing, from $1.08 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.87 in Q4 2022 and troughed at -$12.96 in Q1 2022.
- A 5-year average of -$3.5 and a median of -$3.32 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) sank 1076.19% in 2022, then jumped 256.52% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.87 in 2022, then tumbled by 301.6% to -$3.77 in 2023, then surged by 81.7% to -$0.69 in 2024, then surged by 256.52% to $1.08 in 2025, then slumped by 104.63% to -$0.05 in 2026.
- Business Quant data shows PALI's EPS (Weighted Average and Diluted) at -$0.05 in Q1 2026, $1.08 in Q4 2025, and -$0.38 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - | -0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05 |
| Dec 31, 2025 | 1.08 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.58 |
| Mar 31, 2025 | -0.47 |
| Dec 31, 2024 | -0.69 |
| Sep 30, 2024 | -2.32 |
| Jun 30, 2024 | -3.32 |
| Mar 31, 2024 | -4.59 |
| Dec 31, 2023 | -3.77 |
| Sep 30, 2023 | -7.38 |
| Jun 30, 2023 | -7.93 |
| Mar 31, 2023 | -8.13 |
| Dec 31, 2022 | 1.87 |
| Sep 30, 2022 | -4.10 |
| Jun 30, 2022 | -5.77 |
| Mar 31, 2022 | -12.96 |
| Dec 31, 2021 | -165.61 |
| Sep 30, 2021 | 0.42 |
| Jun 30, 2021 | -4.10 |